Episode Details

Steve and Corey speak with Dr. Michael Kauffman, co-founder and CEO of Karyopharm Therapeutics, about cancer and biotech innovation. Michael explains how he and Dr. Sharon Schacham tested her idea regarding nuclear-transport using simulation software on a home laptop, and went on to beat 1000:1 odds to create a billion dollar company. They discuss the relationship between high proprietary drug costs and economic incentives for drug discovery. They also discuss the unique US biotech ecosystem, and why innovation is easier in small (vs. large) companies. Michael explains how Karyopharm is targeting its drug at COVID-induced inflammation to treat people with severe forms of the disease.

Resources

• Transcript
• Michael Kauffman (Bio)
• Karyopharm’s Publications and Presentations
• The Great American Drug Deal: A New Prescription for Innovative and Affordable Medicines by Peter Kolchinsky

Announcing this for some friends at Mechanize - a startup that builds environments for training and evaluating frontier LLMs. Its customers include the top AI labs, and it has contributed to the breakthrough in coding capabilities of frontier models. 

Mechanize is hiring! 

https://mechanize.work/b/hsu 

Compensation is extremely competitive. For technical roles, $300-500k. They are also seeking smart generalists. 

For example: 

Research Engineer, Alignment: Build evals that test for misaligned model behaviors  $500K salary 

Puzzle Maker: Design interesting and original puzzles that LLMs can’t yet solve  $300K salary 

Mechanize understands that my readership is highly selected. There is a VERY GOOD CHANCE you will be interviewed if you apply via the link above.